January 16, 2023

Amsterdamthe Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company dedicated to improving the lives of people living with severe autoimmune diseases, announced today that an Extraordinary General Meeting of Shareholders will be held on Monday 27 February 2023 at 12:00pm CET at the Hilton Amsterdam Schiphol in Schiphol will be held at Boulevard 701, 1118 BN Schiphol, The Netherlands.

Shareholders and all other persons entitled to attend meetings are invited to attend the extraordinary general meeting. The formal notice (including information on attending the meeting in person or by proxy, registration requirements and registration for the meeting and the e-voting system) is available on argenx’s website www.argenx.com and further www.abnamro.com/evoting.

agenda
The only voting item on the agenda will be the proposed appointment of Mr. Steve Krognes as non-executive director and chairman of the Audit and Compliance Committee of the Company’s Board of Directors.

The full meeting agenda and all supporting documents relevant to the meeting are available on the argenx website and are also available for inspection at argenx offices. A free copy of this can also be requested by email legal@argenx.com. argenx would like to encourage the shareholders to make use of the possibility of voting by (electronic) proxy named in the invitation.

Werner Lanthaler resigns
With the appointment of Mr. Krognes, Werner Lanthaler will step down as non-executive director and chairman of the Audit and Compliance Committee to allow for this important step in the long-term succession planning for the board and the chairman of the Audit and Compliance Committee role. The company would like to thank Werner Lanthaler for his significant contributions over the past eight years. Werner’s entrepreneurial nature combined with extensive experience in finance, business management and life…